On the one hand, the loss of FBP1 promotes tumor progression by enhancing glycolysis and accelerating cancer cells growth, thereby leading to a poor prognosis in patients with breast cancer, pancreatic cancer and liver cancer. Here, FBP1 is linked to breast cancer.